Clinical trial · Interventional
Weekly Versus Three-week Chemoradiation in Patients With Advanced Cervical Cancer
Randomized Trial of Concurrent Chemoradiation With Weekly Versus Three-week Cisplatin in Patients With Advanced Cervical Cancer
NCT01097252CI-TRIAL-00014455completedPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Three weekly cisplatin based chemoradiation is to be compared the compliance, toxicity, and response rates with the weekly cisplatin based chemoradiation in the treatment of locoregionally advanced cervical cancers.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cervical Cancers | Malignant Cervical Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| radiation | Radiation | — | UNRESOLVED |
| tri-weekly cisplatin | Drug | — | UNRESOLVED |
| weekly cisplatin | Drug | Cisplatin | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- weekly cisplatin
- description
- Weekly cisplatin 40mg/m2 during radiation therapy
- interventionNames
- Radiation: radiation
- Drug: weekly cisplatin
- type
- EXPERIMENTAL
- label
- tri-weekly cisplatin
- description
- cisplatin 75mg/m2 three cycles, every 3 weeks
- interventionNames
- Radiation: radiation
- Drug: tri-weekly cisplatin
Primary outcomes (1)
- measure
- compliance
- timeFrame
- 3 month
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 30 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically proven cervical cancer * Squamous, Adenosquamous, Adeno carcinoma cell type * International Federation of Gynecologic Oncology (FIGO) stage IIB - IVA * Gynecologic Oncology Group (GOG) performance status 0 - 2 Exclusion Criteria: * Previous history of chemotherapy or radiation * History of other cancer * Hypersensitivity to platinum agents * Pregnancy * Serious medical disease
References
Publications (1)
- RESULTRyu SY, Lee WM, Kim K, Park SI, Kim BJ, Kim MH, Choi SC, Cho CK, Nam BH, Lee ED. Randomized clinical trial of weekly vs. triweekly cisplatin-based chemotherapy concurrent with radiotherapy in the treatment of locally advanced cervical cancer. Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e577-81. doi: 10.1016/j.ijrobp.2011.05.002. Epub 2011 Aug 11. PMID 21840137